section name header

Basics

Basics

Overview

Narcolepsy/cataplexy refer to the same disorder, cataplexy being the clinical sign easiest to recognize in domestic animals.

Narcolepsy

  • Sleep disorders.
  • Syndrome characterized by excessive sleepiness, cataplexy sleep paralysis, and hypnagogic hallucinations (humans). Sudden episodes of paradoxical sleep without a preceding period of slow-wave sleep.

Cataplexy

  • Sudden, episodic, and spontaneous collapse secondary to complete atonia of skeletal muscles (flaccid paralysis) caused by inhibition of spinal cord lower motor neurons.
  • Patient stays alert and will follow with its eyes.
  • Most common clinical sign of narcolepsy in small animals.

Signalment

  • Dog and rarely cat.
  • Proven hereditary-Labrador retriever, dachshund, and Doberman pinscher.
  • Autosomal recessive gene mutation-canarc-1 gene found on chromosome 12, which codes for a hypocretin (orexin) receptor. Mutations of OxR2 (type II orexin receptor gene). Increased microglial expression of MHC II in Doberman pinscher.
  • Assumed genetic basis for miniature poodle-mode of inheritance unknown.
  • For inherited disease, clinical signs appear between 2 and 4 months of age with escalation of signs around 1 year of age. Possible disappearance of clinical signs later in life.
  • Acquired form may develop in older animals (possible depletion of hypocretin production by hypothalamus) and can occur in any dog breed or mixed breed, at any age.
  • Clinical signs in acquired form will usually remain for life.

Signs

  • Physical and neurologic examinations-normal except during an episode.
  • Onset-peracute.
  • Excessive daytime sleepiness and fragmented sleep patterns reported in domestic animals, but cataplexy is usually the clinical sign recognized by owners.
  • Cataplexy episodes-acute onset of flaccid paralysis without loss of consciousness lasting a few seconds to minutes (up to 20 minutes) with sudden return to normal; multiple episodes in 1 day.
  • Narcolepsy-eye movements, muscular twitching, and whining (as in REM sleep) frequently observed during episodes.
  • Patients are usually aroused by loud noises, petting, or other external stimuli.

Causes & Risk Factors

  • Hereditary in some breeds.
  • Possible immune system involvement in acquired disease.
  • Neurotransmitter abnormalities-serotonin, dopamine, norepinephrine, neuropeptide hypocretin (orexin).
  • Rarely reported with pontomedullary (brainstem) lesions.
  • Excitement, emotions, feeding, and general anesthesia may induce narcoleptic episodes.

Diagnosis

Diagnosis

Differential Diagnosis

  • Syncope.
  • Seizure activity-urinary or fecal incontinence, excessive salivation and muscle rigidity are not characteristic of narcolepsy in which atonia predominates. Recovery after a narcoleptic event is immediate.
  • Non-convulsive seizure (drop attack).
  • Neuromuscular disorders-onset of clinical signs usually not as sudden and recovery not immediate as in narcolepsy.

CBC/Biochemistry/Urinalysis

Normal

Other Laboratory Tests

  • DNA test for specific breeds (Labrador retriever, dachshund, and Doberman pinscher).
  • CSF-normal. Low levels of orexin A in CSF.
  • Standardized food-elicited cataplexy test; play-elicited cataplexy.

Imaging

Brain MRI-normal

Diagnostic Procedures

  • Observe an episode-if a consistent activity (feeding, excitement, etc.) elicits attacks, attempt to simulate the activity.
  • Food-elicited cataplexy test-place 10 pieces of food in a row 12–24 inches apart; record the time required for the patient to eat all the pieces and the number, type, and duration of any attacks that occur; normal dogs eat all food in <45 seconds and have no attacks; affected dogs take >2 minutes to eat the food and can have 2–20 attacks.
  • Play-elicited cataplexy: 2 dogs are left in a room and allowed to interact together and with toys.
  • Physostigmine (cholinesterase inhibitor) challenge to induce cataplexy in an affected dog-administer 0.025–0.1 mg/kg IV; repeat the food-elicited test 5–15 minutes after the injection; increase dosage if necessary (0.05 mg/kg; 0.075 mg/kg; 0.10 mg/kg); effects of each dose last 15–45 minutes.

Treatment

Treatment

Medications

Medications

Drug(s)

Contraindications/Possible Interactions

  • Many patients develop drug tolerance; change of drug may become necessary.
  • Increased heart and respiratory rates, anorexia, tremors, exercise-induced hyperthermia.

Follow-Up

Follow-Up

Miscellaneous

Miscellaneous

Abbreviations

  • CSF = cerebrospinal fluid
  • MRI = magnetic resonance imaging

Author Mylène-Kim Leclerc

Consulting Editor Joane M. Parent

Suggested Reading

De Lahunta A, Glass EN, Kent M. Veterinary Neuroanatomy and Clinical Neurology, 4th ed. Saint Louis, MO: Elsevier Saunders, 2015, pp.491496.